In summary, CYP3A4*18B-20232G/A, UGT2B7-268A/G, and UGT2B7 802C/T wild-type genotypes and CYP3A5*3-6986A/G mutant genotypes are related to the development of ADIH for TB patients receiving anti-TB chemotherapy. This evidence concerns the gene CYP3A5 and tuberculosis.